Durham wants to tour gigapixel camera
DURHAM – A Durham-based company spun out of Duke University is turning to the crowdfunding website Kickstarter to raise money to tour its gigapixel digital camera technology around the state.
The company Aqueti has developed cameras that it says can capture a single moment with 10 times the detail of the human eye, according to a news release. The cameras are made with hundreds of individual cameras that capture images that are then stitched together to create one image with more than a billion pixels, or one gigapixel.
Aqueti is looking to raise $25,000 to tour the camera in North Carolina for three weeks. If it raises the money, company officials plan to host technology demonstrations to allow people to experience the camera hands-on.
The company was founded as a spinoff of Applied Quantum Technologies, a research and development company created as a transition vehicle for Duke University research.
Start-up accelerator to hold pitch day June 6
DURHAM – The leaders of five start-up technology companies involved in the Durham-based technology accelerator program Triangle Startup Factory will pitch their businesses to investors and others June 6.
The TSF Pitch Day is part of the two-day Paradoxos 2013, a festival aimed at showcasing Durham’s entrepreneurial spirit and creative culture.
Triangle Startup Factory’s pitch day event will be held at the Carolina Theatre. Registration is online at www.paradoxos.com. Investors are asked to register at http://tsfpitchday2013.eventbrite.com or to go to the website www.trianglestartupfactory.com.
The festival is slated to include collaborations between technology companies and local breweries, block parties and a discussion called “The Next” at 1 p.m. June 7 that’s sponsored by the Greater Durham Chamber of Commerce.
Liquidia agreement with global health nonprofit extended
MORRISVILLE – Liquidia Technologies’ agreement with the global health nonprofit PATH has been extended, the biotechnology company announced Monday.
The extension allows for the continuation of preclinical proof-of-concept studies on a vaccine to help protect the body against pneumonia, a bacterial disease, according to a company news release.
The company is working on using its PRINT, or Particle Replication In Non-Wetting Templates platform to develop a vaccine that could be helpful in the developing world, where it says they’re often too expensive and don’t protect against all of the different variations of the pneumococcal bacteria.
Founded in 2004, the company is looking to use fabrication techniques of the semiconductor industry to design and manufacture precisely engineered particles using PRINT. It’s looking into using the technology for the development of products in areas such as vaccines, pulmonology, oncology and ophthalmology.